David Reich
Endocrinology, Diabetes & Metabolism · Jamaica, NYNPI 1568541936
Payments from drug & device makers
Across 114 payments — averaging $24.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$663
- Abbott$411
- Pfizer$219
- AstraZeneca$212
- Amgen$202
- Lilly USA, LLC$149
- plus $897 from 16 others
What the payments were for
- Food & beverage$2,754100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 33 | $663 |
| Abbott | 21 | $411 |
| Pfizer | 9 | $219 |
| AstraZeneca(2 entities) | 5 | $212 |
| Amgen(2 entities) | 9 | $202 |
| Lilly USA, LLC | 7 | $149 |
| Corcept Therapeutics | 5 | $138 |
| Amryt Pharma Holdings Ltd | 1 | $125 |
| Sanofi-aventis U.S. LLC | 1 | $117 |
| Amneal Pharmaceuticals LLC | 4 | $95 |
| Insulet Corporation | 3 | $88 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Medtronic | 2 | $54 |
| Vifor Pharma, Inc. | 2 | $40 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $35 |
| Cequr Corporation | 1 | $24 |
| Chiesi USA, Inc. | 1 | $23 |
| Johnson & Johnson | 1 | $22 |
| Merck | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $19 |
| Vivus LLC | 1 | $19 |
| Ferring Pharmaceuticals Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- MYCAPSSA$125
- SOLIQUA 100/33$117
How this compares
$2,754 in reported general payments places this provider in the 60th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
See all endocrinology, diabetes & metabolism providers in New York →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 233 | $377,726 |
| JardianceEmpagliflozin | 211 | $230,768 |
| FarxigaDapagliflozin Propanediol | 221 | $213,949 |
| TrulicityDulaglutide | 125 | $169,641 |
| Somatuline DepotLanreotide Acetate | 12 | $92,237 |
| JanuviaSitagliptin Phosphate | 89 | $71,613 |
| JanumetSitagliptin Phos/Metformin Hcl | 47 | $48,918 |
| ProliaDenosumab | 30 | $48,442 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 129 | $42,651 |
| RybelsusSemaglutide | 29 | $42,220 |
| Tresiba Flextouch U-200Insulin Degludec | 29 | $25,842 |
| Novolog FlexpenInsulin Aspart | 128 | $22,794 |
| MounjaroTirzepatide | 14 | $19,597 |
| Tresiba Flextouch U-100Insulin Degludec | 35 | $15,877 |
| VascepaIcosapent Ethyl | 24 | $14,313 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $663 | $419,947262 claims |
| AstraZenecaFarxiga, Lokelma | $212 | $220,296233 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $149 | $189,238139 claims |
| MerckJanuvia, Janumet, Janumet Xr | $20 | $134,761151 claims |
| AmgenProlia | $202 | $48,44230 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $95 | $1,949142 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 804 endocrinology, diabetes & metabolism providers in New York.
Other endocrinology, diabetes & metabolism in Jamaica
- Robert BuschAlbany$9.1M
- Anastasios ManessisNew York$4.4M
- Ruth WeinstockSyracuse$3.1M
- Adi CohenNew York$2.5M
- Ajay ChaudhuriBuffalo$2.4M
- Carol LevyNew York$2.2M
- Mishaela RubinNew York$2M
- Kenneth HershonNew Hyde Park$1.9M
- Michael ShanikSmithtown$1.7M
- Robert SilverBrooklyn$1.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.